InSite Vision acquired by Sun Pharmaceutical
Advertisement
Drug major Sun Pharmaceutical Industries has recently completed acquisition of the US-based eyecare firm InSite Vision.
The acquisition was completed by means of a short-form merger under the Delaware law, Sun Pharma said in a statement.
Post merger, InSite Vision has become an indirect wholly-owned subsidiary of Sun Pharma.
The company in September had announced its plan to acquire InSite Vision for around $48 million plus related debt and other transaction costs to strengthen its branded ophthalmic portfolio in the US.
The company said each issued and outstanding share of InSite common stock... was converted into the right to receive $0.35 as a result of the merger.
InSite will no longer have reporting obligations under the Securities Exchange Act of 1934 as amended.
"Holders of shares of InSite common stock that did not tender their shares into the tender offer will receive by mail written instructions for surrendering their share certificates or transferring their book-entry shares, including a letter of transmittal, and information regarding the exercise of appraisal rights under the Delaware law," the statement added.
The acquisition was completed by means of a short-form merger under the Delaware law, Sun Pharma said in a statement.
Post merger, InSite Vision has become an indirect wholly-owned subsidiary of Sun Pharma.
The company in September had announced its plan to acquire InSite Vision for around $48 million plus related debt and other transaction costs to strengthen its branded ophthalmic portfolio in the US.
The company said each issued and outstanding share of InSite common stock... was converted into the right to receive $0.35 as a result of the merger.
InSite will no longer have reporting obligations under the Securities Exchange Act of 1934 as amended.
"Holders of shares of InSite common stock that did not tender their shares into the tender offer will receive by mail written instructions for surrendering their share certificates or transferring their book-entry shares, including a letter of transmittal, and information regarding the exercise of appraisal rights under the Delaware law," the statement added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.